| Literature DB >> 26985307 |
Kenia Pissinate1, Anne Drumond Villela2, Valnês Rodrigues-Junior3, Bruno Couto Giacobbo3, Estêvão Silveira Grams1, Bruno Lopes Abbadi3, Rogério Valim Trindade3, Laura Roesler Nery4, Carla Denise Bonan5, Davi Fernando Back6, Maria Martha Campos7, Luiz Augusto Basso7, Diógenes Santiago Santos3, Pablo Machado3.
Abstract
2-(Quinolin-4-yloxy)acetamides have been described as potent in vitro inhibitors of Mycobacterium tuberculosis growth. Herein, additional chemical modifications of lead compounds were carried out, yielding highly potent antitubercular agents with minimum inhibitory concentration (MIC) values as low as 0.05 μM. Further, the synthesized compounds were active against drug-resistant strains and were devoid of apparent toxicity to Vero and HaCat cells (IC50s ≥ 20 μM). In addition, the 2-(quinolin-4-yloxy)acetamides showed intracellular activity against the bacilli in infected macrophages with action similar to rifampin, low risk of drug-drug interactions, and no sign of cardiac toxicity in zebrafish (Danio rerio) at 1 and 5 μM. Therefore, these data indicate that this class of compounds may furnish candidates for future development to, hopefully, provide drug alternatives for tuberculosis treatment.Entities:
Keywords: SAR; Tuberculosis; drug-resistant research; quinoline-based compounds
Year: 2016 PMID: 26985307 PMCID: PMC4789679 DOI: 10.1021/acsmedchemlett.5b00324
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345